|
KMID : 1170320140200030025
|
|
Korean Journal of Health Economics and Policy
2014 Volume.20 No. 3 p.25 ~ p.44
|
|
|
Economic Evaluation of Varenicline and an Existing Smoking Cessation strategy in Korea
|
|
Kim Youn-Hee
Kim Eun-Ju
Park Da-Jin
|
|
|
Abstract
|
|
|
|
This study was conducted to estimate cost-effectiveness of varenicline, a pharmacotherapy developed to support smoking cessation, versus bupropion among prescription drugs. A 30-year Markov model with health states “Smoker”, “Quitter” and “Dead” was used for a hypothetical cohort of Korean smokers who are over 30 years old and willing to quit smoking. Utility values of smokers and quitters incorporated in the model were collected from Korea National Health & Nutrition Examination Survey. Transition probabilities were from clinical trials and Korean statistic data, and cost data were obtained from Korean health insurance reimbursement price list. The model used a 5% discount rate for costs and effectiveness. Sensitivity analyses were conducted on various parameters such as the time to reach mortality rate of ex-smokers compared to that of non-smokers, time horizon and discount rate. The incremental effectiveness of varenicline versus bupropion was 30,408 QALYs. The incremental cost of varenicline versus bupropion was 225 billion KRW. The ICER of varenicline comparing to bupropion was estimated at 7.4 million KRW per QALY. Sensitivity analyses were quite robust for all parameters but it was most sensitive to time horizon. Varenicline treatment for smoking cessation can be considered as cost-effective compared with existing therapies in Korea.
|
|
|
KEYWORD
|
|
|
varenicline, bupropion, Economic evaluation, Cost, Smoking Cessation Strategy, varenicline, bupropion
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|